A Multi-centre, Flexible Dose, Parallel Group, Open-label, Active Control (Calcium-based Phosphate Binder), Long-term Extension Study Evaluating the Efficacy, Safety and Tolerability of Colestilan (MCI-196) in Paediatric Subjects With Hyperphosphataemia and With Either Chronic Kidney Disease Stage 5 on Dialysis or Chronic Kidney Disease Stages 3b to 5 Not on Dialysis
Latest Information Update: 10 Apr 2023
At a glance
- Drugs Colestilan (Primary) ; Colestilan (Primary) ; Phosphate binding protein modulators
- Indications Hyperphosphataemia; Kidney disorders
- Focus Therapeutic Use
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 26 May 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 16 Oct 2013 New trial record